As of 2026-10-10, the EV/EBITDA ratio of Shield Therapeutics PLC (STX.L) is -25.77. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. STX.L's latest enterprise value is 81.54 mil GBP. STX.L's TTM EBITDA according to its financial statements is -3.16 mil GBP. Dividing these 2 quantities gives us the above STX.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 5.1x - 6.1x | 5.7x |
| Forward P/E multiples | 6.4x - 7.6x | 7.2x |
| Fair Price | (2.99) - (2.91) | (3.01) |
| Upside | -156.4% - -155.0% | -156.9% |
| Date | EV/EBITDA |
| 2026-10-07 | -26.65 |
| 2026-10-06 | -27.07 |
| 2026-10-05 | -28.47 |
| 2026-10-02 | -28.59 |
| 2026-10-01 | -28.74 |
| 2026-09-30 | -28.66 |
| 2026-09-29 | -27.07 |
| 2026-09-28 | -26.57 |
| 2026-09-25 | -25.68 |
| 2026-09-24 | -24.09 |
| 2026-09-23 | -24.13 |
| 2026-09-22 | -23.78 |
| 2026-09-21 | -23.82 |
| 2026-09-18 | -23.74 |
| 2026-09-17 | -23.51 |
| 2026-09-16 | -22.97 |
| 2026-09-15 | -22.81 |
| 2026-09-14 | -23.44 |
| 2026-09-11 | -23.59 |
| 2026-09-10 | -24.29 |
| 2026-09-09 | -24.90 |
| 2026-09-08 | -25.33 |
| 2026-09-07 | -28.98 |
| 2026-09-04 | -26.84 |
| 2026-09-03 | -26.81 |
| 2026-09-02 | -27.81 |
| 2026-09-01 | -25.91 |
| 2026-08-28 | -29.17 |
| 2026-08-27 | -26.61 |
| 2026-08-26 | -24.52 |
| 2026-08-25 | -24.17 |
| 2026-08-24 | -23.63 |
| 2026-08-21 | -24.32 |
| 2026-08-20 | -24.29 |
| 2026-08-19 | -22.39 |
| 2026-08-18 | -22.43 |
| 2026-08-17 | -22.47 |
| 2026-08-14 | -22.39 |
| 2026-08-13 | -22.74 |
| 2026-08-12 | -21.61 |
| 2026-08-11 | -20.68 |
| 2026-08-10 | -20.34 |
| 2026-08-07 | -20.26 |
| 2026-08-06 | -20.22 |
| 2026-08-05 | -20.84 |
| 2026-08-04 | -19.72 |
| 2026-08-03 | -20.72 |
| 2026-07-31 | -20.84 |
| 2026-07-30 | -22.35 |
| 2026-07-29 | -27.62 |